Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera’s integrated sacral neuromodulation system
Pezzella said she believes Neuspera offers a “smart, integrated, sophisticated alternative” for treating overactive bladder symptoms.
Related Articles
Survey: New NMIBC treatments face slow uptake
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Navigating Treatment Decisions in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Prostate Size and Its Effect on Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Improvement After Convective Water Vapor Thermal Therapy | Journal of Urology
Purpose:Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) affect quality of life. Convective water vapor thermal therapy (CWVTT; Rezūm) is a minimally…
EAU Guidelines on the Management of Non-neurogenic Male LUTS – DISEASE MANAGEMENT – Uroweb
These EAU Guidelines offer practical evidence-based guidance on the assessment and treatment of men aged 40 years or older with various non-neurogenic benign forms of…
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
The level II code A9616 will be effective starting on October 1, 2025.
Supplemental Medical Review Contractor (SMRC) – Noridian – SMRC
Medical Records Request Scam: Watch out for Phishing CMS identified phishing scams for medical records. This may include scammers faxing you fraudulent medical records requests…
Market-Level Features May Influence a Hospital’s Decision to Perform Robotic Radical Cystectomy in Florida | Urology Practice
Introduction:Adoption of robotic radical cystectomy (RC) occurred before the availability of randomized data supporting oncologic noninferiority of this approach. We hypothesized that market-level features may…
Intermediate-Term Oncologic Outcomes of Partial Nephrectomy vs Cryoablation in Renal Tumors > 3 cm: A Propensity Score–Matched Analysis | Journal of Urology
Purpose:Cryoablation (CA) and partial nephrectomy (PN) are effective nephron-sparing treatments of small renal masses. While guidelines list thermal ablation as an option for tumors <…
Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC
The company said it plans to report interim efficacy data from the trial in September 2025.